Loading patent…
AssigneeKing Faisal University
InventorsMAHMOUD KANDEEL ELSAYED, ABDULLA YOUSEF AL-TAHER, HYUNG-JOO KWON, MOHAMMED AL-NAZAWI
Estimating the term…
The MERS-CoV inhibitor peptides include a set of peptides designed by modification or mutation of a wild type MERS-CoV fusion protein. The MERS-CoV inhibitor peptides are capable of inhibition of MERS-CoV membrane fusion, and thereby may prevent or slow the spread of MERS-CoV infections. Thus, the MERS-CoV inhibitor peptides may be used in pharmaceuticals to prevent and/or treat MERS-CoV infection. The pharmaceuticals may be formulated to comprise at least one of the MERS-CoV inhibitor peptides and a carrier, or they may include one or more expression systems capable of promoting cellular expression of one or more MERS-CoV inhibitor peptides. The MERS-CoV inhibitor peptides may also be used as reagents for MERS-CoV inhibition assays as a standard or reference inhibitors.
1-5. (canceled)
A method for conducting a MERS CoV inhibition assay comprising using a MERS CoV inhibitor as a standard or as a reference inhibitor, wherein the MERS CoV inhibitor comprises a peptide having the amino acid sequence selected from the group consisting of SEQ ID NOs:
A pharmaceutical composition consisting of a MERS CoV inhibitor and a pharmaceutically acceptable carrier, wherein the MERS CoV inhibitor comprises a peptide having the amino acid sequence selected from the group consisting of SEQ ID NOs:
10-14. (canceled)
A method of preventing MERS CoV infection of a cell comprising:
-19. (canceled)
Dependencies are inferred from the claim text.